ReviewCureus2025
Clinical Significance, Differential Diagnosis and Initial Management of Hematuria in Emergency and Outpatient Settings.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A forgotten disease revisited: giant bladder stone in a modern clinical setting case report.Journal of surgical case reports · 2026Article
- Article
- Impact of a vertically integrated, symptom-oriented teaching program for hematuria management on clinical competency transfer among urology clerkship students.BMC medical education · 2026Article
- Primary Localized Amyloidosis of the Urinary Bladder Mimicking Urothelial Carcinoma: A Case Report.Cureus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematuria is a common clinical symptom that may reflect a wide spectrum of underlying conditions, ranging from benign etiologies to potentially life-threatening diseases such as urothelial carcinoma or renal trauma. It is generally classified as either gross (visible) or microscopic (detected only through urinalysis), and particularly in emergency settings, it requires prompt and structured evaluation to guide further diagnostic and therapeutic decisions. Delayed recognition may result in missed malignancies or avoidable complications, underscoring the importance of early and accurate assessment at the initial point of medical contact. This review offers a comprehensive overview of the early management of hematuria, with particular emphasis on emergency and outpatient care settings. It highlights practical strategies for triage, differential diagnosis, and identification of high-risk patients, while providing evidence-based guidance on indications for referral and hospitalization. The analysis is grounded in a broad review of the current literature from 2016 to 2025, incorporating international guidelines and expert recommendations to ensure relevance and clinical applicability. Ultimately, hematuria should never be underestimated during the initial clinical encounter. A systematic approach that integrates risk stratification and adherence to current guidelines allows for timely detection of serious underlying pathologies, such as malignancy or obstructive uropathy. Recognizing alarm features, such as gross hematuria, anemia, persistent symptoms, or impaired renal function, is essential for initiating appropriate diagnostic pathways, expediting specialist referral, and improving overall patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.